Trial Profile
A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Fulvestrant; Fulvestrant
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms VERONICA
- Sponsors Roche
- 10 Dec 2022 This trial has been completed in Germany (Date of the global end of the trial: 05-May-2021), according to the European Clinical Trials Database record.
- 21 Jun 2022 Status changed from completed to discontinued.
- 18 May 2022 Primary analysis (at data cutoff: 5 August 2020; n = 103) assessing venetoclax and fulvestrant in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer patients, published in the Clinical Cancer Research